Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Retained Earnings: 2015-2024

Historic Retained Earnings for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to -$978.1 million.

  • Seres Therapeutics' Retained Earnings rose 0.56% to -$957.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$957.1 million, marking a year-over-year increase of 0.56%. This contributed to the annual value of -$978.1 million for FY2024, which is 0.01% up from last year.
  • Seres Therapeutics' Retained Earnings amounted to -$978.1 million in FY2024, which was up 0.01% from -$978.2 million recorded in FY2023.
  • Seres Therapeutics' Retained Earnings' 5-year high stood at -$548.8 million during FY2020, with a 5-year trough of -$978.2 million in FY2023.
  • Its 3-year average for Retained Earnings is -$940.3 million, with a median of -$978.1 million in 2024.
  • In the last 5 years, Seres Therapeutics' Retained Earnings slumped by 40.72% in 2022 and then grew by 0.01% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Retained Earnings stood at -$548.8 million in 2020, then decreased by 11.95% to -$614.4 million in 2021, then crashed by 40.72% to -$864.5 million in 2022, then fell by 13.15% to -$978.2 million in 2023, then increased by 0.01% to -$978.1 million in 2024.